CoChat

The complex pathway between amyloid β and cognition: implications for therapy

Jagust, William J, Teunissen, Charlotte E, DeCarli, Charles · 2023 · The Lancet Neurology
Cited by 71

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1474-4422(23)00128-x

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 41 references

Research works printed but not linked: 54

  1. Hardy, 2002, The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics, Science, 297, 353, 10.1126/science.1072994 · DOI · Paper page
  2. Aisen, 2020, The future of anti-amyloid trials, J Prev Alzheimers Dis, 7, 146, 10.14283/jpad.2020.24 · DOI · Paper page
  3. Ackley, 2021, Effect of reductions in amyloid levels on cognitive change in randomized trials: instrumental variable meta-analysis, BMJ, 372, n156, 10.1136/bmj.n156 · DOI · Paper page
  4. Budd Haeberlein, 2022, Two randomized phase 3 studies of aducanumab in early Alzheimer's disease, J Prev Alzheimers Dis, 9, 197, 10.14283/jpad.2022.30 · DOI · Paper page
  5. van Dyck, 2023, Lecanemab in early Alzheimer's disease, N Engl J Med, 388, 9, 10.1056/NEJMoa2212948 · DOI · Paper page
  6. Villemagne, 2018, Imaging tau and amyloid-β proteinopathies in Alzheimer disease and other conditions, Nat Rev Neurol, 14, 225, 10.1038/nrneurol.2018.9 · DOI · Paper page
  7. Boulo, 2020, First amyloid β1-42 certified reference material for re-calibrating commercial immunoassays, Alzheimers Dement, 16, 1493, 10.1002/alz.12145 · DOI · Paper page
  8. Morris, 2022, Autosomal dominant and sporadic late onset Alzheimer's disease share a common in vivo pathophysiology, Brain, 145, 3594, 10.1093/brain/awac181 · DOI · Paper page
  9. Farrell, 2022, Association of emerging β-amyloid and tau pathology with early cognitive changes in clinically normal older adults, Neurology, 98, e1512, 10.1212/WNL.0000000000200137 · DOI
  10. Tideman, 2022, Association of β-amyloid accumulation with executive function in adults with unimpaired cognition, Neurology, 98, e1525, 10.1212/WNL.0000000000013299 · DOI
  11. Pereira, 2021, Untangling the association of amyloid-β and tau with synaptic and axonal loss in Alzheimer's disease, Brain, 144, 310, 10.1093/brain/awaa395 · DOI · Paper page
  12. Betthauser, 2020, Amyloid and tau imaging biomarkers explain cognitive decline from late middle-age, Brain, 143, 320, 10.1093/brain/awz378 · DOI · Paper page
  13. Chen, 2021, Regional tau effects on prospective cognitive change in cognitively normal older adults, J Neurosci, 41, 366, 10.1523/JNEUROSCI.2111-20.2020 · DOI
  14. Harrison, 2021, Distinct effects of beta-amyloid and tau on cortical thickness in cognitively healthy older adults, Alzheimers Dement, 17, 1085, 10.1002/alz.12249 · DOI
  15. Guo, 2021, Longitudinal cognitive and biomarker measurements support a unidirectional pathway in Alzheimer's disease pathophysiology, Biol Psychiatry, 89, 786, 10.1016/j.biopsych.2020.06.029 · DOI · Paper page
  16. Weigand, 2020, Is tau in the absence of amyloid on the Alzheimer's continuum?: a study of discordant PET positivity, Brain Commun, 2, 10.1093/braincomms/fcz046 · DOI · Paper page
  17. Yoon, 2022, Abnormal tau in amyloid PET negative individuals, Neurobiol Aging, 109, 125, 10.1016/j.neurobiolaging.2021.09.019 · DOI
  18. Strikwerda-Brown, 2022, Association of elevated amyloid and tau positron emission tomography signal with near-term development of Alzheimer disease symptoms in older adults without cognitive impairment, JAMA Neurol, 79, 975, 10.1001/jamaneurol.2022.2379 · DOI · Paper page
  19. Wardlaw, 2013, Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration, Lancet Neurol, 12, 822, 10.1016/S1474-4422(13)70124-8 · DOI · Paper page
  20. Koncz, 2018, Are the brain's vascular and Alzheimer pathologies additive or interactive?, Curr Opin Psychiatry, 31, 147, 10.1097/YCO.0000000000000395 · DOI
  21. Soldan, 2020, White matter hyperintensities and CSF Alzheimer disease biomarkers in preclinical Alzheimer disease, Neurology, 94, e950, 10.1212/WNL.0000000000008864 · DOI · Paper page
  22. DeCarli, 2019, Vascular burden score impacts cognition independent of amyloid PET and MRI measures of Alzheimer's disease and vascular brain injury, J Alzheimers Dis, 68, 187, 10.3233/JAD-180965 · DOI
  23. Altendahl, 2020, An IL-18-centered inflammatory network as a biomarker for cerebral white matter injury, PLoS One, 15, 10.1371/journal.pone.0227835 · DOI
  24. Hughes, 2013, Pulse wave velocity is associated with β-amyloid deposition in the brains of very elderly adults, Neurology, 81, 1711, 10.1212/01.wnl.0000435301.64776.37 · DOI · Paper page
  25. Reed, 2012, Coronary risk correlates with cerebral amyloid deposition, Neurobiol Aging, 33, 1979, 10.1016/j.neurobiolaging.2011.10.002 · DOI · Paper page
  26. Rapp, 2020, Effects of intensive versus standard blood pressure control on domain-specific cognitive function: a substudy of the SPRINT randomised controlled trial, Lancet Neurol, 19, 899, 10.1016/S1474-4422(20)30319-7 · DOI · Paper page
  27. Kim, 2018, Assessment of extent and role of tau in subcortical vascular cognitive impairment using 18F-AV1451 positron emission tomography imaging, JAMA Neurol, 75, 999, 10.1001/jamaneurol.2018.0975 · DOI · Paper page
  28. Hu, 2022, Tau pathologies mediate the association of blood pressure with cognitive impairment in adults without dementia: the CABLE study, Alzheimers Dement, 18, 53, 10.1002/alz.12377 · DOI
  29. Thomas, 2020, Association of TDP-43 proteinopathy, cerebral amyloid angiopathy, and Lewy bodies with cognitive impairment in individuals with or without Alzheimer's disease neuropathology, Sci Rep, 10, 10.1038/s41598-020-71305-2 · DOI · Paper page
  30. Nelson, 2022, Frequency of LATE neuropathologic change across the spectrum of Alzheimer's disease neuropathology: combined data from 13 community-based or population-based autopsy cohorts, Acta Neuropathol, 144, 27, 10.1007/s00401-022-02444-1 · DOI · Paper page
  31. Power, 2018, Combined neuropathological pathways account for age-related risk of dementia, Ann Neurol, 84, 10, 10.1002/ana.25246 · DOI · Paper page
  32. Filshtein, 2019, Neuropathological diagnoses of demented Hispanic, Black, and non-Hispanic White decedents seen at an Alzheimer's disease center, J Alzheimers Dis, 68, 145, 10.3233/JAD-180992 · DOI · Paper page
  33. Wilkins, 2022, Racial and ethnic differences in amyloid PET positivity in individuals with mild cognitive impairment or dementia: a secondary analysis of the Imaging Dementia-Evidence for Amyloid Scanning (IDEAS) cohort study, JAMA Neurol, 79, 1139, 10.1001/jamaneurol.2022.3157 · DOI · Paper page
  34. Boyle, 2021, To what degree is late life cognitive decline driven by age-related neuropathologies?, Brain, 144, 2166, 10.1093/brain/awab092 · DOI · Paper page
  35. Brosseron, 2022, Soluble TAM receptors sAXL and sTyro3 predict structural and functional protection in Alzheimer's disease, Neuron, 110, 1009, 10.1016/j.neuron.2021.12.016 · DOI · Paper page
  36. Whitwell, 2018, Imaging correlations of tau, amyloid, metabolism, and atrophy in typical and atypical Alzheimer's disease, Alzheimers Dement, 14, 1005, 10.1016/j.jalz.2018.02.020 · DOI · Paper page
  37. Rabin, 2019, Vascular risk and β-amyloid are synergistically associated with cortical tau, Ann Neurol, 85, 272, 10.1002/ana.25399 · DOI · Paper page
  38. Koscik, 2020, Amyloid duration is associated with preclinical cognitive decline and tau PET, Alzheimers Dement, 12
  39. Schindler, 2021, Predicting symptom onset in sporadic Alzheimer disease with amyloid PET, Neurology, 97, e1823, 10.1212/WNL.0000000000012775 · DOI · Paper page
  40. Das, 2021, Tau-atrophy variability reveals phenotypic heterogeneity in Alzheimer's disease, Ann Neurol, 90, 751, 10.1002/ana.26233 · DOI · Paper page
  41. Arenaza-Urquijo, 2018, Resistance vs resilience to Alzheimer disease: clarifying terminology for preclinical studies, Neurology, 90, 695, 10.1212/WNL.0000000000005303 · DOI · Paper page
  42. Hohman, 2016, Asymptomatic Alzheimer disease: defining resilience, Neurology, 87, 2443, 10.1212/WNL.0000000000003397 · DOI · Paper page
  43. Seto, 2022, Exploring common genetic contributors to neuroprotection from amyloid pathology, Brain Commun, 4, 10.1093/braincomms/fcac066 · DOI
  44. La Joie, 2021, Association of APOE4 and clinical variability in Alzheimer disease with the pattern of tau- and amyloid-PET, Neurology, 96, e650, 10.1212/WNL.0000000000011270 · DOI · Paper page
  45. Weigand, 2021, APOE interacts with tau PET to influence memory independently of amyloid PET in older adults without dementia, Alzheimers Dement, 17, 61, 10.1002/alz.12173 · DOI · Paper page
  46. Chhatwal, 2022, Variant-dependent heterogeneity in amyloid β burden in autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analyses of an observational study, Lancet Neurol, 21, 140, 10.1016/S1474-4422(21)00375-6 · DOI · Paper page
  47. Jagust, 2021, Temporal dynamics of β-amyloid accumulation in aging and Alzheimer disease, Neurology, 96, e1347, 10.1212/WNL.0000000000011524 · DOI · Paper page
  48. Landau, 2018, Memory decline accompanies subthreshold amyloid accumulation, Neurology, 90, e1452, 10.1212/WNL.0000000000005354 · DOI · Paper page
  49. Farrell, 2018, Regional amyloid accumulation and cognitive decline in initially amyloid-negative adults, Neurology, 91, e1809, 10.1212/WNL.0000000000006469 · DOI · Paper page
  50. Tosun, 2017, Association between tau deposition and antecedent amyloid-β accumulation rates in normal and early symptomatic individuals, Brain, 140, 1499, 10.1093/brain/awx046 · DOI · Paper page
  51. Leal, 2018, Subthreshold amyloid predicts tau deposition in aging, J Neurosci, 38, 4482, 10.1523/JNEUROSCI.0485-18.2018 · DOI · Paper page
  52. Bejanin, 2019, Antemortem volume loss mirrors TDP-43 staging in older adults with non-frontotemporal lobar degeneration, Brain, 142, 3621, 10.1093/brain/awz277 · DOI
  53. Lesman-Segev, 2021, Diagnostic accuracy of amyloid versus 18F-fluorodeoxyglucose positron emission tomography in autopsy-confirmed dementia, Ann Neurol, 89, 389, 10.1002/ana.25968 · DOI · Paper page
  54. Raman, 2022, Dynamic amyloid PET: relationships to 18F-flortaucipir tau PET measures, J Nucl Med, 63, 287, 10.2967/jnumed.120.254490 · DOI

Cited by

See all 71

Metadata

Authors
Jagust, W. J., Teunissen, C. E., & DeCarli, C.
Venue
The Lancet Neurology
Publisher
Elsevier BV
Published
2023-09
Volume
22
Issue
9
Pages
847-857
ISSN
1474-4422
Cited by
71
References
41
Language
en
Funders
  • National Institutes of Health (AG024904, AG034570, AG062542, AG072972, AG075758, NS120384)
  • Health~Holland
  • European Commission
  • Dutch Research Council

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The complex pathway between amyloid β and cognition: implications for therapy. https://app.cochat.ai/papers/10.1016/s1474-4422(23)00128-x
The paper
Jagust, W. J., Teunissen, C. E., & DeCarli, C. (2023). The complex pathway between amyloid β and cognition: implications for therapy. The Lancet Neurology. https://doi.org/10.1016/s1474-4422(23)00128-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.